

कर्मचारी राज्य वीमा लिगम (श्रम एव रोज़गार मत्रात्य,भारत सरकार) EMPLOYEES' STATE INSURANCE CORPORATION (Ministry of Labour & Employment, Govt. of India)



मुख्यालय/HEADQUARTERS पंचदीप भवन, सी.आई.जी मार्ग, नई दिल्ली -110 002 PanchdeepBhawan,C.I.G. Marg,New Delh-110002 www.esic.gov.in, 35011-23604773, <u>dmc-rc@esic.nic.in</u>

File No.:e-U-25/12/NSQ/2022-MedV(E-12328) 302 Dated: /05/2025

To, Director (Medical) Delhi / Director (Medical) Noida, Dean, All ESIC PGIMSR's, Medical & Dental Colleges Medical Superintendents – All ESIC Hospitals, Directors, ESI Scheme, All States

NSQ/05/2025

Subject: Declaration of Drug "Not of Standard Quality" on Testing - reg

Sir/Madam

It is hereby informed that the Drug/item has been reported as "Not of Standard Quality" as detailed below:

Reported		Item Name/ Brand Name	RC No/ Item No/ Page No		Name of the Laboratory/ Repor No. & Date	Reason of NSQ
ESIC Model Hospital, Baddi, H.P	Healthcare	Amoxycillin+ Clavulanate+ lactic Acid Bacillus Tab/Cap- Each Tab/Cap to contain: Amoxycillin Trihydrate Eqv. to Amoxycillin 500 mg, Clavulanate Potassium Eqv. to Clavulanic Acid 125mg, lactic Acid Bacillus - 60 Million Spores Augpen LB 625	22	ZO5AF24052 08/2024 01/2026	Drug Testing Laboratory, Baddi	does not conformsto claim as per Patent & Proprietary in

In context to above, it is directed that:

1. Stop use of the batch of the above-mentioned item immediately which has been reported as "Not of Standard Quality" (copy enclosed).

2. Replacement of supplies or cost of the materials is to be recovered along with testing charges (if any) from the firm.

3. Initiate action as per clause for 'Testing of Drugs-Quality Control" of Terms & Conditions of respective DG-ESIC Tender Enquiry/RC.

4. Maintain record of action taken at respective user units.

e-U-25/12/NSQ/2022-MedV I(12328) Contd. to pre page:

This issues with the approval of Medical Commissioner (Procurement).

Yours Faithfully,

Enclosures: As above

Digitally signed by Sanjiv Kochhar Date: 27-05-2025 Dy.12403033 Commissioner (RC)

Copy to:

- 1. The Drug Controller General of India, CDSCO, CIG Road, New Delhi-110002 (dci@nic.in).
- The State Drug Controller, Food and Drug Administration, Survey No. 341, 2nd Floor, Bandra Kurla Complex, Opposite RBI, Kala Nagar, Bandra East, Mumbai-400051 (whogmp.mahafda@gmail.com) with the request to take appropriate action on NSQ reported for the above said batch under information to this office (copy of test report enclosed).
- 3. State Drug Controller, Controlling cum Licensing Authority, Baddi, Himachal Pradesh-173205 (Email:sdc4hp@gmail.com).
- 4. Food & Drug Administration, Gangtok, Sikkim-737101 (Email:sikkimdrugcontrol@gmail.com)
- 5. M/s Zuventus Healthcare Limited, Zuventus House, Plot Y2, CTS No.358/A2, Near Nahur Railway Station, Nahar (West), Mumbai-400078 (Emailsheetal.khanvilkar@zuventus.com, Nilesh.Nabar@zuventus.com.in
- 6. M/s Zuventus Healthcare Limited, Kamerey bhasmay, elaka, pakyong Rangpo, East Sikkim-737131 (Email id:enquiry@zuventus.com)
- 7. Website Content Manager with request for uploading on ESIC website.
- 8. Guard file.

Email

Fwd: Regarding Tab amoxycillin pottasium clavulanate and lactic acid bacillus tablet (Augpen LB 625) BATCH Z05AF 24052 MFG 8/26 AND EXP 1/26 " NOT OF STANDARD QUALITY

From : DMC RC <dmc-rc@esic.nic.in>

Subject : Fwd: Regarding Tab amoxycillin pottasium clavulanate and lactic acid bacillus tablet (Augpen LB 625) BATCH Z05AF 24052 MFG 8/26 AND EXP 1/26 " NOT OF STANDARD QUALITY

Wed, May 21, 2025 12:46 PM 2 attachments

To:RCCell <rc-hqrs@esic.gov.in>

Reply To : DMC RC <dmc-rc@esic.nic.in>

महोदय/महोदया,

उपरोक्त विषयांतर्गत आपके सादर सूचनार्थ एवं आवश्यक कार्रवाई हेतु संलग्नक प्रेषित है।

Please find herein attachment for your kind information & necessary action.

धन्यवाद, उप चिकित्सा आयुक्त (आर सी व पीसी, शाखा ५) क रा बी निगम मुख्यालय VOIP No. 10011026

From: "S S" <ms-baddi.hp@esic.nic.in>
To: "DMC RC" <dmc-rc@esic.nic.in>, "DMC Procurement" <dmc-procurement.hq@esic.gov.in>
Sent: Wednesday, May 21, 2025 12:04:09 PM
Subject: Regarding Tab amoxycillin pottasium clavulanate and lactic acid bacillus tablet (Augpen LB 625) BATCH Z05AF 24052 MFG 8/26 AND EXP 1/26 " NOT OF STANDARD QUALITY

महोदय/महोदया, Sir/Madam,

> उपरोक्त विषयांतर्गत आपके सादर सूचनार्थ एवं आवश्यक कार्रवाई हेतु संलग्नक प्रेषित है। Please find herein attachment for your kind information & necessary action.

Generated from eOffice by RAMESH KUMAR SAINI, PHA-MED5-RKS, PHARMACIST, Employees State Insurance Corporation (ESIC) on 22/05/2025 11:33 am of 2

सादर धन्यवाद/Thanks & regards.....

चिकित्सा अधीक्षक/Medical superintendent, क.रा.बी.निगम आदर्श अस्पताल, बद्दी (हि. प्र.) ESIC Model Hospital, Baddi (H.P)

From: "ROHIT KAUSHIK" <dr.rohit.kaushik@esic.nic.in>
To: "S S" <ms-baddi.hp@esic.nic.in>
Cc: "Dr. Sugeet Tandon" <dr.sugeet.tandon@esic.nic.in>
Sent: Wednesday, May 21, 2025 11:10:03 AM
Subject: Regarding Tab amoxycillin pottasium clavulanate and lactic acid bacillus tablet (Augpen LB 625) BATCH Z05AF 24052 MFG 8/26 AND EXP 1/26 " NOT OF STANDARD QUALITY

Respected Madam,

Kindly find attachment of Letter To Dy Medical Commissioner (RC) regarding Tab amoxycillin pottasium clavulanate and lactic acid bacillus tablet (Augpen LB 625) BATCH Z05AF 24052 MFG 8/26 AND EXP 1/26 " NOT OF STANDARD QUALITY", Now MS may like to see and if agree and send this letter to ESIC HQ Dy Medical Commissioner (RC) for further necessary action.

With Regards Dr Rohit Kaushik CMS ESIC MH BADDI H.P



sample report.pdf 721 KB

File No. e-U-25/12/NSQ/2022-MedV (Computer No. 12328)



कर्मचारी राज्य बीमा निगम श्रम एवं रोजगार मंत्रालय, **भारत सरकार**) EMPLOYEE'S STATE INSURANCE CORPORATION



आदर्श अस्पताल / Model Hospital गॉवः काठा, बद्दी, जिलाः सोलन, हिमाचल प्रदेशः 173205 Village-Katha, Baddi, District:Solan, Himachal Pradesh-173205 Phone: 01795-275105, 275106, E.mail: ms-baddi.hp@esic.nic.in Website: www.esic.nic.in/ www.esichospitals.gov.in/ www.esic.in

EComp. No.:226898 226898 File No.:142/U-16/02/16/Testingofdrugs/Pharmacy ..

Date-19/05/2025

То

Dy. Medical Commissioner (rate contract) ESIC Panchdeep Bhawan,

Comrade Inderjeet Gupta (CIG) Marg.

New Delhi-110002

Sub-Regarding Not Of Standard quality of the sample amoxycillin pottasium clavulanate and lactic acid bacillus tablet (Augpen LB 625 Tab).

Sir.

This is to inform you that the below-mentioned drug has been declared as "NOT OF STANDARD QUALITY" and it has been directed to stop use of the batch of the drug immediately by the drug inspector, Baddi, HP. vide letter Ref No.FDA/Sales-2025-56, mail received on Dated-19/05/25.

S n o	mp le No	Product (Name and content)	Batch No.	Mfg date, Expir y Date	RC No	Mfd. by	Report No. & Date	NSQ Re ported b y
1	ESI/ 01	(Augpen LB 625 Tab). Amoxycillin+Clavulanate +Lactic Acid Bacillus Tab /Cap- Each Tab/Cap to contain: Amoxycillin Trihydrate Eqv. to Amoxy cillin 500mg, Clavulanat e Potassium Eqv. to Clav ulanic Acid 125mg, lactic Acid Bacillus - 60 Million Spores-AUGPEN LB 625	Z05AF 24052	8/24, 01/26	157	Zuventus Healt hcare Limited, kemerey Bhas my, elka,Pakyo ng, Rangpo, Ea st Sikkim, 737132	No. DH SR/DTL / Report/	Drug Insp ector O/o State Drug Cont roller Baddi, Dis tt. Solan Himachal Pradesh

Sample taken on Date-15/01/2025

The report is attached for your information and further necessary action.

This has also been intimated to the firm and O/o State Drug Controller, Baddi, HP.

This letter is Approved and Signed after Approval by Competent Authority.

Rohit Kaushik, IMO-CMS-RK, Central Medical Store 21-05-2025

4721539/2025/SEC-MED 5-ESICHQ

-	N .		FORM 13				
			(See rule 46)		64	D (
C	ertificate of test of	r analysis by Govern	ment Analyst und metics Act, 1940	er section 25 (1)	of the	Drugs and	
		Cost	mencs Act, 1940				
	CI Company	whom received	: 4	Akshay Kumar, Dru	igs Ins	spector HQ Baddi	
	of Inspector from		m :F	DA/Sales-2024-48	0, Dat	ted: 15/01/2025	
		spectors memorandu	:E	ESI/01			
	er of Sample		: 1	6/01/2025			
. Date o	of receipt	to be contained in t	he sample :				
		ng to be contained in t Batch No.	Date of Mfg.	Date of Exp.	Mi	fg. By	
Sample			08/2024	01/2026	_	Zuventus Healthcard Limited Kamerey Bhasmay Elaka, Pakyong Rangpo, East Sikkin	
Amoxy		ZUSAF24032	00/2021		Lir		
Clavular Acid Ba	cillus Tablets	<			Ka		
					Ela		
(AUG	SPEN-LB® 625)			- 9			
	¥ .					7132, India.	
6.Condi	tion of seals on			ls were intact & ide			
The nac	ket or on portion of	sample or container)	•			ed from Drugs Insp	
7. Result	t of test or analysis	with protocols of test	or analysis applied	for the Sample No	b LSD/	/DTL/0206/24-25	
	Compositio	n: Each Filmcoa	ated tablet is purpo	rted to contains:			
	Compositio		ated tablet is purpo n Trihydrate	rted to contains: IP			
	Compositio	Amoxycilli	n Trihydrate	IP	0 mg		
	Compositio	Amoxycillin Eq to A		IP 50	0 mg		
	Compositio	Amoxycillin Eq to A Potassium	n Trihydrate Amoxycillin Clavulanate Dilute	IP 50 ed IP	0 mg 5 mg		
	Compositio	Amoxycillin Eq to A Potassium Eq to C	n Trihydrate Amoxycillin Clavulanate Dilute Clavulanic Acid	IP 50 ed IP 12	5 mg	n spores	
	Compositio	Amoxycillin Eq to A Potassium Eq to C Lactic A	n Trihydrate Amoxycillin Clavulanate Dilute Clavulanic Acid Acid Bacillus	IP 50 ed IP 12: 60	5 mg	on spores	
	Compositio	Amoxycillin Eq to A Potassium Eq to C Lactic A	n Trihydrate Amoxycillin Clavulanate Dilute Clavulanic Acid	IP 50 ed IP 12: 60	5 mg	on spores	
Sr.No		Amoxycillin Eq to A Potassium Eq to C Lactic A	n Trihydrate Amoxycillin Clavulanate Dilute Clavulanic Acid Acid Bacillus	IP 50 ed IP 12: 60	5 mg	on spores Limits	
Sr.No	Test Name	Amoxycillin Eq to A Potassium Eq to C Lactic A <u>Protocol</u>	n Trihydrate Amoxycillin Clavulanate Dilute Clavulanic Acid Acid Bacillus Applied : Patent Result	IP 50 ed IP 12: 60 <u>& Proprietarv</u>	5 mg millio	-	
Sr.No 1.		Amoxycillin Eq to A Potassium Eq to C Lactic A <u>Protocol</u> Lig	n Trihydrate Amoxycillin Clavulanate Dilute Clavulanic Acid Acid Bacillus	IP 50 50 50 22 60 <u>& Proprietarv</u> , Oval, biconvex, f	5 mg millio ilm	Limits	
	Test Name	Amoxycillin Eq to A Potassium Eq to C Lactic A <u>Protocol</u> Lig coa	n Trihydrate Amoxycillin Clavulanate Dilute Clavulanic Acid Acid Bacillus Applied : Patent Result Sht Yellow coloured	IP 50 50 50 22 60 <u>& Proprietarv</u> , Oval, biconvex, f	5 mg millio ilm	Limits	
1.	Test Name Description	Amoxycillin Eq to A Potassium Eq to C Lactic A <u>Protocol</u> Lig coa	n Trihydrate Amoxycillin Clavulanate Dilute Clavulanic Acid Acid Bacillus Applied : Patent Result tht Yellow coloured ated tablet plain on b	IP 50 50 50 22 60 <u>& Proprietarv</u> , Oval, biconvex, f	5 mg millio ilm	Limits	
1. 2.	Test Name Description Identification	Amoxycillin Eq to A Potassium Eq to C Lactic A <u>Protocol</u> Lig coa alu	n Trihydrate Amoxycillin Clavulanate Dilute Clavulanic Acid Acid Bacillus Applied : Patent Result Sht Yellow coloured ated tablet plain on b -alu blister pack.	IP 50 ed IP 12: 60 <u>& Proprietarv</u> , Oval, biconvex, f both sides. Packed i	5 mg millio ilm	Limits NA	
1.	Test Name Description	Amoxycillin Eq to A Potassium Eq to C Lactic A <u>Protocol</u> Lig coa alu	n Trihydrate Amoxycillin Clavulanate Dilute Clavulanic Acid Acid Bacillus Applied : Patent Result Sht Yellow coloured ated tablet plain on b -alu blister pack.	IP 50 ed IP 12: 60 <u>& Proprietary</u> , Oval, biconvex, f both sides. Packed i	5 mg millio ilm	Limits	
1. 2. (a)	Test Name Description Identification By HPLC	Amoxycillin Eq to A Potassium Eq to C Lactic A Protocol Lig coa alu Pos Pot	n Trihydrate Amoxycillin Clavulanate Dilute Clavulanic Acid Acid Bacillus Applied : Patent Result the tablet plain on b -alu blister pack.	IP 50 ed IP 12: 60 <u>& Proprietary</u> , Oval, biconvex, f both sides. Packed i	5 mg millio ilm	Limits NA	
1. 2.	Test Name Description Identification	Amoxycillin Eq to A Potassium Eq to C Lactic A Protocol Lig coa alu Pos Pot	n Trihydrate Amoxycillin Clavulanate Dilute Clavulanic Acid Acid Bacillus Applied : Patent Result Sht Yellow coloured ated tablet plain on b -alu blister pack.	IP 50 ed IP 12: 60 <u>& Proprietary</u> , Oval, biconvex, f both sides. Packed i	5 mg millio ilm	Limits NA	
1. 2. (a)	Test Name Description Identification By HPLC	Amoxycillin Eq to A Potassium Eq to C Lactic A <u>Protocol</u> Lig coa alu Pos Pot	n Trihydrate Amoxycillin Clavulanate Dilute Clavulanic Acid Acid Bacillus Applied : Patent Result the tablet plain on b -alu blister pack.	IP 50 ed IP 12: 60 <u>& Proprietary</u> , Oval, biconvex, f both sides. Packed i	5 mg millio ilm	Limits NA	
1. 2. (a) (b)	Test Name Description Identification By HPLC By Microscopical Average Weight	Amoxycillin Eq to A Potassium Eq to C Lactic A Protocol Lig coa alu Pos Pot Iy Pos	n Trihydrate Amoxycillin Clavulanate Dilute Clavulanic Acid Acid Bacillus Applied : Patent Result Sht Yellow coloured ated tablet plain on b -alu blister pack. Sitive for Amoxycilli assium Clavulanate. Sitive for Lactic acid 4.795 mg	IP 50 ed IP 12: 60 <u>& Proprietary</u> , Oval, biconvex, f both sides. Packed i	5 mg millio ilm	Limits NA NA	
1. 2. (a) (b) 3.	Test Name Description Identification By HPLC By Microscopical	Amoxycillin Eq to A Potassium Eq to C Lactic A Protocol Lig coa alu Pos Pot Iy Pos 1094	n Trihydrate Amoxycillin Clavulanate Dilute Clavulanic Acid Acid Bacillus Applied : Patent Result the Yellow coloured ated tablet plain on b -alu blister pack.	IP 50 ed IP 12: 60 <u>& Proprietary</u> , Oval, biconvex, f both sides. Packed i	5 mg millio ilm	Limits NA NA	

Contd.....

File No. e-U-25/12/NSQ/2022-MedV (Computer No. 12328)

Generated from eOffice by RAMESH KUMAR SAINI, PHA-MED5-RKS, PHARMACIST, Employees State Insurance Corporation (ESIC) on 22/05/2025 11:33 am

S. No	Ingredient Name	Found	Claim	% of Claim	Limits	Procedure/ Method
1.	Amoxycillin Trihydrate calculated as Amoxycillin	388.43 mg	500 mg	77.69 %	90% - 120%	DTL/STP/QC/081
2	Potassium Clavulanate Diluted calculated as Clavulanic Acid	126.45 mg	125 mg	101.16 %	90% - 120%	DTL/STP/QC/081
3.	Lactic acid Bacillus	67.52 million spores	60 million spores	112.53%	NLT 90%	DTL/STP/QC/081

In the opinion of the undersigned the sample referred to above is **not of standard quality** as defined in Drugs and Cosmetics Act, 1940, and Rules there under for the reason given below:

The Sample does not conforms to claim as per Patent & Proprietary in respect to the Assay of Amoxycillin.

Government Annivst:

Deepika Banyal Government Analyst Drugs Testing Laboratory, Baddi Distt. Solan(H.P.) 173205

No. DHSR/DTL/Report/25-26- 0887

Date: 13 05 2025

Dated: 13 05 2025

.....END OF REPORT.....

Generated from eOffice by RAMESH KUMAR SAINI, PHA-MED5-RKS, PHARMACIST, Employees State Insurance Corporation (ESIC) on 22/05/2025 11:33 am

Health and Family Welfare Department Himachal Pradesh

Sal4.201-5-6

From

Ref.-:

Drug Inspector, HQ Baddi, Distt. Solan H.P.

TO

ESIC Model Hospital, Katha Baddi, Distt. Solan H.P.

Regarding Not of standard quality declaration of the sample of Amoxycillin Pottasium Clavulanate and Lactic Acid Bacillus Tablets, Batch No. ZO5AF24052, Mfg date08/2024 & Exp. Date 01/2026 Manufacturing by M/s Zuventus Healthcare Limited Kamerey Bhasmay, Elaka, Pakyong Rangpo, East Sikkim 737132.

Memo,

A sample of Amoxycillin Pottasium Clavulanate and Lactic Acid Bacillus Tablets, Batch No. ZO5AF24052, Mfg date08/2024 & Exp. Date 01/2026 Manufacturing by M/s Zuventus Healthcare Limited Kamerey Bhasmay, Elaka, Pakyong Rangpo, East Sikkim 737132 was taken by Drug Inspector Baddi for the purpose of testing and analysis on 15.01.2025 from a premises ESIC Model Hospital Situated at Katha Baddi, Distt. Solan H.P. . The sample was sent to the DTL Baddi who was declared it as not of standard quality vide his report no. DHSR/DTL/Report/25-26-0887 dated 13.05.2025 for the reason cited in the report (Annexure-A original). You are directed to provide attested copy of purchase invoices of total quantity above said product & further to stop the distribution of said product. You reply in this regard should be submitted to this office in Seven days of receipt of this letter positively.

Akshay Kumar Drugsinspector H.O. Baddi, Distt. Solah (H.P.) Akshay Kumar

Drugs Inspector, O/o State Drugs Controller, Baddi, Distt. Solan Himachal Pradesh,

Generated from eOffice by RAMESH KUMAR SAINI, PHA-MED5-RKS, PHARMACIST, Employees State Insurance Corporation (ESIC) on 22/05/2025 11:33 am